Abcuro
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
$66MSeries D
Role not disclosedSV
Sanofi Ventures
Activity from announced rounds
Activity in this selectionlifearc-0377a910
- Rounds participated in
- 8
- Confirmed lead rounds
- — 8 roles undisclosed
- New companies
- 8 First participation on record · 0 follow-on
- Funding in participating rounds
- $947M 8 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
8 in this selectionEpicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedQuantHealth
AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment
$45MSeries B
Role not disclosedAdvanCell
Develops lead-212 targeted alpha therapies to treat cancer
$315MSeries D
Role not disclosedDraig Therapeutics
Developing transformative, best-in-class neuropsychiatric therapies
$65MSeries B
Role not disclosedBionyra Pharma
Developing next-generation biologics for severe immunological and inflammatory diseases
$165MSeries A
Role not disclosedBranchLab
Builds AI platform helping pharma companies identify, activate and optimize patient and HCP audiences
$26MSeries A
Role not disclosedKorsana Biosciences
Develops novel therapies to reduce the burden of neurodegenerative diseases
$175MSeries A
Role not disclosed